|
|
Volumn 352, Issue 6293, 2016, Pages 1506-
|
|
Beleaguered phage therapy trial presses on: Setbacks suggest difficult road for much-needed antibiotic alternatives
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBIOTIC AGENT;
SULFADIAZINE;
ANTIINFECTIVE AGENT;
ANTIBACTERIAL ACTIVITY;
ANTIBIOTIC RESISTANCE;
BACTERIOPHAGE;
DRUG INDUSTRY;
ESCHERICHIA COLI INFECTION;
HUMAN;
NONHUMAN;
NOTE;
PHAGE THERAPY;
PRIORITY JOURNAL;
PSEUDOMONAS INFECTION;
BACTERIOLYSIS;
BIOLOGICAL THERAPY;
COMMUNICABLE DISEASES;
EUROPE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PROCEDURES;
ANTI-BACTERIAL AGENTS;
BACTERIOLYSIS;
BACTERIOPHAGES;
BIOLOGICAL THERAPY;
CLINICAL TRIALS, PHASE I AS TOPIC;
CLINICAL TRIALS, PHASE II AS TOPIC;
COMMUNICABLE DISEASES;
DRUG RESISTANCE, BACTERIAL;
EUROPE;
HUMANS;
|
|
EID: 84975824517
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.352.6293.1506 Document Type: Note |
|
Times cited : (39)
|
|
References (0)
|